NCT00382213View on ClinicalTrials.gov

A Randomized, Double Blind Study To Compare The Effects Of Olmesartan Medoxomil Versus Placebo In Patients With Established Atherosclerosis

PHASE3CompletedINTERVENTIONAL
Enrollment

210

Participants

Timeline

Start Date

June 30, 2000

Study Completion Date

December 31, 2004

Conditions
Atherosclerosis
Interventions
DRUG

Olmesartan medoxomil

DRUG

Placebo

Sponsors

Lead Sponsor

Daiichi Sankyo
All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY

NCT00382213 - A Randomized, Double Blind Study To Compare The Effects Of Olmesartan Medoxomil Versus Placebo In Patients With Established Atherosclerosis | Biotech Hunter | Biotech Hunter